Lorenzo Antonuzzo

Perioperative Durvalumab for Resectable Non–Small-Cell Lung Cancer

John V. Heymach, David H. Harpole, Tetsuya Mitsudomi et al. · New England Journal of Medicine · 2023 · 574 citations · Full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 246 citations · Full text

Oncology, Clinical Trials, Colorectal Cancer +9

Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

Thomas Powles, James W.F. Catto, Matthew D. Galsky et al. · New England Journal of Medicine · 2024 · 245 citations · Full text

Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial

Gianluca Masi, Lisa Salvatore, Luca Boni et al. · Annals of Oncology · 2015 · 164 citations · Full text

Gastrointestinal Oncology, Medicine, Randomized Bebyp Trial +7